知搜-全球专利检索

  1. Login
  2. Sign Up

Search Results

42 records (took 0.031 seconds)

    Creatine prodrugs, compositions and methods of use thereof
    1.
    发明授权
    Creatine prodrugs, compositions and methods of use thereof 有权

    公开(公告)号：US10344007B2

    公开(公告)日：2019-07-09

    申请号：US15481568

    申请日：2017-04-07

    Applicant: Farmington Pharma Development

    Inventor： William F. Brubaker

    IPC: C07D273/06 ,  C07C279/14 ,  C07C279/24 ,  C07D271/07 ,  C07D273/04

    Abstract: The invention describes membrane permeable creatine prodrugs, pharmaceutical compositions comprising membrane permeable creatine prodrugs, and methods of treating diseases such as ischemia, heart failure, neurodegenerative disorders and genetic disorders affecting the creatine kinase system comprising administering creatine prodrugs or pharmaceutical compositions thereof. The invention also describes treating a genetic disease affecting the creatine kinase system, such as, for example, a creatine transporter disorder or a creatine synthesis disorder comprising administering creatine prodrugs or pharmaceutical compositions thereof.

    Pharmaceutical Uses of Staurosporine Derivatives
    2.
    发明申请
    Pharmaceutical Uses of Staurosporine Derivatives 有权
    星孢菌素衍生物的药物用途

    公开(公告)号：US20070299049A1

    公开(公告)日：2007-12-27

    申请号：US10560669

    申请日：2004-06-17

    Applicant: Steven Coutre

    Inventor： Steven Coutre

    IPC: A61K31/553 ,  A61P37/08 ,  C07D273/06

    CPC classification number: C07D498/16 ,  A61K31/553

    Abstract: This application relates to the use of staurosporines derivatives for the curative, palliative or prophylactic treatment of allergic rhinitis, allergic dermatitis, drug allergy or food allergy, angioedema, urticaria, sudden infant death syndrome, bronchopulmonary aspergillosis, multiple sclerosis, or mastocytosis; and to a method of treatment of warm-blooded animals in which a therapeutically effective dose of a compound of a Staurosporine Derivative is administered to a warm-blooded animal suffering from one of the diseases or conditions mentioned above.

    Abstract translation: 本申请涉及星孢菌素衍生物用于过敏性鼻炎，过敏性皮炎，药物过敏或食物过敏，血管性水肿，荨麻疹，婴儿猝死综合征，支气管肺曲霉病，多发性硬化症或肥大细胞增多症的治疗性，姑息治疗或预防性治疗的用途。 以及治疗温血动物的方法，其中将治疗有效剂量的星孢菌素衍生物化合物施用于患有上述疾病或病症的温血动物。

    Process for the preparation of '1,4,5!-oxadiazepine derivatives
    3.
    发明申请
    Process for the preparation of '1,4,5!-oxadiazepine derivatives 有权
    制备'1,4,5'-恶二氮杂衍生物的方法

    公开(公告)号：US20050159313A1

    公开(公告)日：2005-07-21

    申请号：US10498865

    申请日：2002-12-17

    Applicant: Beat Jau ,  Marian Parak

    Inventor： Beat Jau ,  Marian Parak

    IPC: C07D273/06 ,  A01N25/00 ,  C07D285/36

    CPC classification number: C07D273/06

    Abstract: A process for the preparation of [1,4,5]-oxadiazepine derivatives by reaction of N,N′-diacyl-hydrazines with 2,2′-disubstituted diethyl ethers to form 4,5-diacyl-[1,4,5]-oxadiazepines and reaction of the latter compounds with a hydrohalic acid.

    Abstract translation: 通过N，N'-二酰基 - 肼与2,2'-二取代二乙醚的反应制备[1,4,5] - 恶二氮杂衍生物的方法，形成4,5-二酰基 - [1,4,5 ] - 恶二唑并将后者与氢卤酸反应。

    5-Benzoylamino-1,3-dioxacyclanes, the method for preparing the same and their use as PKC inhibitor
    4.
    发明申请
    5-Benzoylamino-1,3-dioxacyclanes, the method for preparing the same and their use as PKC inhibitor 审中-公开
    5-苯甲酰氨基-1,3-二氧环己烷，其制备方法及其作为PKC抑制剂的用途

    公开(公告)号：US20050043396A1

    公开(公告)日：2005-02-24

    申请号：US10674148

    申请日：2003-09-29

    Applicant: Hayley Zen ,  Shiqi Peng ,  Lanrong Bi ,  Ming Zhao ,  Chao Wang

    Inventor： Hayley Zen ,  Shiqi Peng ,  Lanrong Bi ,  Ming Zhao ,  Chao Wang

    IPC: C07D273/06 ,  C07D319/06 ,  C07D321/12 ,  A61K31/335

    CPC classification number: C07D319/06 ,  C07D273/06 ,  C07D321/12

    Abstract: The present invention discloses a series of benzoylamino-1,3-dioxacyclane compounds, of which compounds 1-21 were prepared via transacetalisation reaction between N-benzoylaminoglycol and 1,1,3,3-tetramethoxypropane; while compounds 22-48 were prepared via stereospecific acetalisation reaction between N-benzoylamino glycol and aromatic aldehyde, and if necessary, the nitro groups were reduced and further be salified with propane diacid and L-Arg or L-Lys. These compounds possess the structural type of PKC inhibitor and positive anti-inflammatory effect, and can be applied in medical fields as PKC inhibitor for corresponding therapy.

    Abstract translation: 本发明公开了一系列苯甲酰基氨基-1,3-二氧杂环烷化合物，其中化合物1-21是通过N-苯甲酰氨基甘氨酸与1,1,3,3-四甲氧基丙烷之间的转化反应制备的; 而化合物22-48通过N-苯甲酰氨基二醇和芳族醛之间的立体特异性缩醛化反应制备，并且如果需要，硝基还原，并进一步用丙烷二酸和L-Arg或L-Lys进行成盐。 这些化合物具有PKC抑制剂的结构型和阳性消炎作用，可作为PKC抑制剂用于医学领域，用于相应的治疗。

    CREATINE PRODRUGS, COMPOSITIONS AND METHODS OF USE THEREOF
    6.
    发明申请
    CREATINE PRODRUGS, COMPOSITIONS AND METHODS OF USE THEREOF 审中-公开

    公开(公告)号：US20190337909A1

    公开(公告)日：2019-11-07

    申请号：US16419596

    申请日：2019-05-22

    Applicant: FARMINGTON PHARMA DEVELOPMENT

    Inventor： William F. BRUBAKER

    IPC: C07D273/06 ,  C07C279/24 ,  C07D273/04 ,  C07C279/14 ,  C07D271/07

    Abstract: The invention describes membrane permeable creatine prodrugs, pharmaceutical compositions comprising membrane permeable creatine prodrugs, and methods of treating diseases such as ischemia, heart failure, neurodegenerative disorders and genetic disorders affecting the creatine kinase system comprising administering creatine prodrugs or pharmaceutical compositions thereof. The invention also describes treating a genetic disease affecting the creatine kinase system, such as, for example, a creatine transporter disorder or a creatine synthesis disorder comprising administering creatine prodrugs or pharmaceutical compositions thereof.

    CREATINE PRODRUGS, COMPOSITIONS AND METHODS OF USE THEREOF
    7.
    发明申请
    CREATINE PRODRUGS, COMPOSITIONS AND METHODS OF USE THEREOF 有权
    CREATINE PRODRUGS，COMPOSITIONS AND METHODS OF USE THEREOF

    公开(公告)号：US20160176829A1

    公开(公告)日：2016-06-23

    申请号：US14975950

    申请日：2015-12-21

    Applicant: Farmington Pharma Development

    Inventor： William F. Brubaker

    IPC: C07D273/06 ,  C07D271/07 ,  C07D273/04 ,  C07C279/14

    CPC classification number: C07D273/06 ,  C07B2200/05 ,  C07C279/14 ,  C07C279/24 ,  C07D271/07 ,  C07D273/04

    Abstract: The invention describes membrane permeable creatine prodrugs, pharmaceutical compositions comprising membrane permeable creatine prodrugs, and methods of treating diseases such as ischemia, heart failure, neurodegenerative disorders and genetic disorders affecting the creatine kinase system comprising administering creatine prodrugs or pharmaceutical compositions thereof. The invention also describes treating a genetic disease affecting the creatine kinase system, such as, for example, a creatine transporter disorder or a creatine synthesis disorder comprising administering creatine prodrugs or pharmaceutical compositions thereof.

    Abstract translation: 本发明描述了膜渗透性肌酸酐前药，包含膜可渗透性肌酸酐前药的药物组合物，以及治疗疾病如缺血，心力衰竭，神经变性疾病和影响肌酸激酶系统的遗传病症的方法，包括给予肌酸前药或其药物组合物。 本发明还描述了治疗影响肌酸激酶系统的遗传疾病，例如肌酸转运蛋白紊乱或肌酸合成障碍，其包括施用肌酸前药或其药物组合物。

Patent Agency Ranking